Literature DB >> 24286582

Management of the ACC/AHA Stage D patient: mechanical circulatory support.

David A Baran1, Abhishek Jaiswal.   

Abstract

From humble beginnings in 1963 with a single desperately ill patient, mechanical circulatory support has expanded exponentially to where it is a viable alternative for advanced heart failure patients. Some of these patients are awaiting transplant but others will have a mechanical heart pump as their ultimate treatment. The history of MCS devices is reviewed, along with the 4 trials that define the modern era of circulatory support. The practical aspects of life with an MCS device are reviewed and common problems encountered with MCS devices. Future trends including miniaturization and development of completely contained MCS systems are reviewed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced heart failure; Device malfunction; Mechanical circulatory support

Mesh:

Substances:

Year:  2014        PMID: 24286582     DOI: 10.1016/j.ccl.2013.09.013

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  3 in total

Review 1.  The State of the Science on Integrating Palliative Care in Heart Failure.

Authors:  Laura P Gelfman; Marie Bakitas; Lynne Warner Stevenson; James N Kirkpatrick; Nathan E Goldstein
Journal:  J Palliat Med       Date:  2017-05-12       Impact factor: 2.947

Review 2.  Direct Cardiac Cellular Reprogramming for Cardiac Regeneration.

Authors:  Vivekkumar Patel; Megumi Mathison; Vivek P Singh; Jianchang Yang; Todd K Rosengart
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-09

3.  Prognostic Awareness and Goals of Care Discussions Among Patients With Advanced Heart Failure.

Authors:  Laura P Gelfman; Rebecca L Sudore; Harriet Mather; Karen McKendrick; Mathew D Hutchinson; Rachel J Lampert; Hannah I Lipman; Daniel D Matlock; Keith M Swetz; Sean P Pinney; R Sean Morrison; Nathan E Goldstein
Journal:  Circ Heart Fail       Date:  2020-09-02       Impact factor: 8.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.